ESMO Breast Cancer 2023 Congress Coverage


 

ESMO Breast Cancer 2023 EMERALD Trial: Analysis of PROs in Patients With ER+/HER2- Advanced or Metastatic BC Comparing Oral Elacestrant vs. Standard of Care ET

502 views
May 22, 2023
Comments 0
Login to view comments. Click here to Login